

PEP needs some pep! Addressing PEP Neglect in HIV Prevention Research, Programming and Uptake

Date: Thursday, Nov 3, 2022

Shared Informational Resources

The Choice Agenda https://www.avac.org/choice-agenda

TCA webinar: "More than Vessels: Pregnant people deserve inclusion in HIV prevention clinical and implementation research" Wednesday, December 14, 2022 at 9:00am-10:30am ET; 1:00pm-2:30pm GMT <u>https://tinyurl.com/morethanvessels</u>

CDC PEP resource page https://www.cdc.gov/hiv/risk/pep/index.html

PEP Basics via Aidsmap https://www.aidsmap.com/about-hiv/post-exposure-prophylaxis-pep

Enabling timely HIV postexposure prophylaxis access in sub-Saharan Africa https://journals.lww.com/aidsonline/Fulltext/2022/08010/Enabling_timely_HIV_postexposure_prophyl axis.20.aspx

Home packs cut time to start HIV 'morning after pill' by two-thirds <u>https://www.aidsmap.com/news/may-2022/home-packs-cut-time-start-hiv-morning-after-pill-two-thirds</u>

The characteristics of men who have sex with men (MSM) using post-exposure prophylaxis for sexual exposure (PEPSE) in the pre-exposure prophylaxis (PrEP) era https://pubmed.ncbi.nlm.nih.gov/34725897/

Immediate PrEP after PEP: Results from an Observational Nurse-Led PEP2PrEP Study https://pubmed.ncbi.nlm.nih.gov/32856549/

What do patients consulting in a free sexual health center know about HIV transmission and postexposure prophylaxis?

https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-021-10547-9

A Case–Control Study of HIV Seroconversion in Health Care Workers after Percutaneous Exposure <u>https://www.nejm.org/doi/full/10.1056/nejm199711203372101</u>

Can the promotion of post-exposure prophylaxis following sexual exposure to HIV (PEPSE) cause harm? <u>https://sti.bmj.com/content/81/3/190.1.full</u>

Seroconversion following Nonoccupational Postexposure Prophylaxis against HIV <u>https://www.jstor.org/stable/4463561</u>

MMWR – Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5011a1.htm

Schechter M. Program and abstracts of the Sixth International Congress on Drug Therapy in HIV Infection; November 17-21, 2002; Glasgow. Abstract PL6.1 <u>https://aidsetc.org/sites/default/files/resources_files/nw_pep.ppt</u>

Post-exposure prophylaxis for SIV revisited: Animal model for HIV prevention https://aidsrestherapy.biomedcentral.com/articles/10.1186/1742-6405-3-29

Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV— United States, 2016 https://www.cdc.gov/hiv/pdf/programresources/cdc-hiv-npep-guidelines.pdf

Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure <u>https://journals.lww.com/jaids/Abstract/2022/05010/Safety_and_Tolerability_of_Once_Daily_Coformul_ated.5.aspx</u>

Synthesis of Post-Exposure Prophylaxis (PEP) Policies in MOSAIC Countries https://www.prepwatch.org/wp-content/uploads/2022/07/MOSAIC_PEPPolicySynthesisBrief_FINAL.pdf

Uptake and outcomes of a novel community-based HIV post-exposure prophylaxis (PEP) programme in rural Kenya and Uganda https://onlinelibrary.wiley.com/doi/full/10.1002/jia2.25670

PEP for HIV prevention: are we missing opportunities to reduce new infections? <u>https://onlinelibrary.wiley.com/doi/full/10.1002/jia2.25942</u>